CDKN2B and astrocytoma (excluding glioblastoma): As reported before [16, 26, 41], presence of a CDKN2A/CDKN2B homozygous deletion is associated with particularly poor outcome of IDH-mutant astrocytoma patients, even within the group of patients with CNS WHO grade 4 tumors [26].